Title:miRNAs Modulate the Dichotomy of Cisplatin Resistance or Sensitivity in Breast Cancer: An Update of Therapeutic Implications
VOLUME: 21 ISSUE: 9
Author(s):Asma Safi, Milad Bastami, Soheila Delghir, Khandan Ilkhani, Farhad Seif and Mohammad R. Alivand*
Affiliation:Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences, Tabriz, Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences, Tabriz, Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Department of Immunology & Allergy, Academic Center for Education, Culture, and Research, Tehran, Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences, Tabriz
Keywords:Cisplatin, breast cancer, drug resistance, miRNAs, EMT, cancer stem cell.
Abstract:Cisplatin has a broad-spectrum antitumor activity and is widely used for the treatment of various
malignant tumors. However, acquired or intrinsic resistance of cisplatin is a major problem for patients during
the therapy. Recently, it has been reported Cancer Stem Cell (CSC)-derived drug resistance is a great challenge
of tumor development and recurrence; therefore, the sensitivity of Breast Cancer Stem Cells (BCSCs) to cisplatin
is of particular importance. Increasing evidence has shown that there is a relationship between cisplatin
resistance/sensitivity genes and related miRNAs. It is known that dysregulation of relevant miRNAs plays a
critical role in regulating target genes of cisplatin resistance/sensitivity in various pathways such as cellular
uptake/efflux, Epithelial-Mesenchymal Transition (EMT), hypoxia, and apoptosis. Furthermore, the efficacy of
the current chemotherapeutic drugs, including cisplatin, for providing personalized medicine, can be improved
by controlling the expression of miRNAs. Thus, potential targeting of miRNAs can lead to miRNA-based therapies,
which will help overcome drug resistance and develop more effective personalized anti-cancer and cotreatment
strategies in breast cancer. In this review, we summarized the general understandings of miRNAregulated
biological processes in breast cancer, particularly focused on the role of miRNA in cisplatin resistance/
sensitivity.
